Monday March 13, 8:30 am Eastern Time
Company Press Release
NeoPharm Files Investigational New Drug Application for IL-13 PE38QQR in Brain Cancer
BANNOCKBURN, IL--(BUSINESS WIRE)--March 13, 2000--NeoPharm, Inc. (AMEX: NEO - news) announced today it has filed an investigational new drug application (IND) for IL-13 PE38QQR (``IL-13'), a novel ligand targeted cytotoxin for the treatment of glioblastoma (brain cancer). IL-13 targets receptors on the cell surface of the tumor and delivers a potent toxin PE38.
``Glioblastoma is an extremely lethal form of brain cancer which currently lacks effective treatments,' said James M. Hussey, Chief Executive Officer of NeoPharm. ``The pre-clinical data on IL-13 is extremely promising and led us to file this IND to initiate human clinical trials.'
``We hope to initiate trials with IL-13 for the treatment of glioblastoma during the next few months,' said Dr. Aquilur Rahman, Chief Scientific Officer of NeoPharm. ``The submission of this IND demonstrates the rapid development of this ligand-targeted cytotoxin as a new modality of treatments for brain cancer. If effective and safe in clinical treatment, IL-13 could be an important addition to brain cancer therapy.'
NeoPharm, Inc., based in Bannockburn, Illinois, is a publicly traded biopharmaceutical company dedicated to the discovery and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a broad portfolio of cancer compounds in various stages of development. |
